184 related articles for article (PubMed ID: 15767326)
1. What happened to the coxibs on the way to the cardiologist?
Alberts DS; Potter JD; Martinez ME; Hess LM; Stopeck A; Lance P
Cancer Epidemiol Biomarkers Prev; 2005 Mar; 14(3):555-6. PubMed ID: 15767326
[No Abstract] [Full Text] [Related]
2. Learning the value of drugs--is rofecoxib a regulatory success story?
Eisenberg RS
N Engl J Med; 2005 Mar; 352(13):1285-7. PubMed ID: 15800222
[No Abstract] [Full Text] [Related]
3. Raising the safety bar--the FDA's coxib meeting.
Okie S
N Engl J Med; 2005 Mar; 352(13):1283-5. PubMed ID: 15800221
[No Abstract] [Full Text] [Related]
4. Drug safety. Withdrawal of Vioxx casts a shadow over COX-2 inhibitors.
Couzin J
Science; 2004 Oct; 306(5695):384-5. PubMed ID: 15486258
[No Abstract] [Full Text] [Related]
5. How to avoid another 'Vioxx'.
Frantz S
Nat Rev Drug Discov; 2005 Jan; 4(1):5-7. PubMed ID: 15690595
[No Abstract] [Full Text] [Related]
6. Under surveillance.
Nat Biotechnol; 2005 Jan; 23(1):1. PubMed ID: 15637596
[No Abstract] [Full Text] [Related]
7. The Vioxx debacle revisited.
Mohapatra PR; Janmeja AK
Am J Med; 2005 Sep; 118(9):1058. PubMed ID: 16164909
[No Abstract] [Full Text] [Related]
8. A tale of two coxibs.
Hegmann T
JAAPA; 2005 Mar; 18(3):14, 17. PubMed ID: 15789666
[No Abstract] [Full Text] [Related]
9. Rofecoxib, Merck, and the FDA.
Villalba L; Witter J
N Engl J Med; 2004 Dec; 351(27):2875-8; author reply 2875-8. PubMed ID: 15625745
[No Abstract] [Full Text] [Related]
10. Cardiovascular complications of COX2 selective inhibitors cause considerable concern.
Hedner T; Himmelmann A
Blood Press; 2004; 13(5):260-1. PubMed ID: 15545147
[No Abstract] [Full Text] [Related]
11. [The rise and fall of Vioxx: society, values and their choice].
Caspi D
Harefuah; 2004 Nov; 143(11):770-1. PubMed ID: 15603261
[No Abstract] [Full Text] [Related]
12. Health Canada lukewarm on Vioxx panel findings.
Murray S
CMAJ; 2005 Aug; 173(4):350. PubMed ID: 16103502
[No Abstract] [Full Text] [Related]
13. The Vioxx debacle revisited.
Daikh DI
Am J Med; 2005 Sep; 118(9):1057. PubMed ID: 16164908
[No Abstract] [Full Text] [Related]
14. Evaluating drug effects in the post-Vioxx world: there must be a better way.
Avorn J
Circulation; 2006 May; 113(18):2173-6. PubMed ID: 16684873
[No Abstract] [Full Text] [Related]
15. The Vioxx debacle revisited.
Good CB; Kelley CL
Am J Med; 2005 Sep; 118(9):1055-6; author reply 1056-7. PubMed ID: 16164902
[No Abstract] [Full Text] [Related]
16. Don't throw out the baby with the bathwater!
Kamen B; Kieran M
J Pediatr Hematol Oncol; 2005 Feb; 27(2):59-60. PubMed ID: 15701976
[No Abstract] [Full Text] [Related]
17. What ails the FDA?
Okie S
N Engl J Med; 2005 Mar; 352(11):1063-6. PubMed ID: 15784660
[No Abstract] [Full Text] [Related]
18. COX-2 inhibitor use after Vioxx: careful balance or end of the rope?
Fendrick AM
Am J Manag Care; 2004 Nov; 10(11 Pt 1):740-1. PubMed ID: 15623263
[No Abstract] [Full Text] [Related]
19. [Cardiovascular risk: a class effect of coxibs? How to manage patients taking Vioxx?].
Brune K; Zacher J
MMW Fortschr Med; 2004 Oct; 146(42):10, 12. PubMed ID: 15536697
[No Abstract] [Full Text] [Related]
20. The pain game.
Wadman M
Nature; 2007 Jul; 448(7152):400-1. PubMed ID: 17653159
[No Abstract] [Full Text] [Related]
[Next] [New Search]
